As anti-cancer therapies that target a single RTK often result in the rapid emergence of resistant cells, the identification of molecular mechanisms that could provide compensatory growth signaling in the absence of IGF-IR activation is critical for the design of effective combination therapies. The gene discussed is IGF1R; the disease is cancer.